Experience

Davis Polk advised the sole book-running manager and representative of the several underwriters in connection with a $63.3 million SEC-registered offering of 6,325,000 shares of common…

Davis Polk is advising Aetna Inc. in connection with the sale by Aetna and Humana Inc. of certain of their respective Medicare Advantage assets to Molina Healthcare, Inc. for a total…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $719 million initial public offering by Patheon N.V. (“Patheon”). The IPO comprised…

Davis Polk acted as special product counsel to the representatives of the initial purchasers in connection with an SEC-registered offering by Intercept Pharmaceuticals, Inc. of an aggregate…

Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Universal American Corp. of an aggregate principal amount of $115 million of 4.00% convertible senior…

Davis Polk advised the joint book-running managers in connection with the $120 million follow-on offering of common stock of Global Blood Therapeutics, Inc. Global Blood’s common stock is…

Davis Polk advised the representative of the underwriters in connection with the $181 million public offering of 4,025,000 shares of common stock of Spark Therapeutics, Inc. (“Spark”),…

Davis Polk advised the representatives of the several underwriters, in connection with an SEC-registered offering by Nevro Corp. of $172.5 million aggregate principal amount of its 1.75%…

Davis Polk advised the joint bookrunners in connection with a Rule 144A offering by The Medicines Company of $402.5 million aggregate principal amount of 2.75% convertible senior notes due…

Davis Polk advised Aetna Inc. on its SEC-registered notes offering of $13 billion aggregate principal amount of senior notes in eight series, consisting of $500 million aggregate principal…